Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Equities researchers at HC Wainwright cut their FY2025 earnings per share estimates for shares of Merus Labs International in a report issued on Thursday, March 27th. HC Wainwright analyst A. He now expects that the specialty pharmaceutical company will earn ($0.19) per share for the year, down from their prior estimate of ($0.18). HC Wainwright also issued estimates for Merus Labs International’s FY2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.22) EPS.
Merus Labs International Stock Performance
The company has a fifty day moving average price of C$1.65. Merus Labs International has a 52-week low of C$0.95 and a 52-week high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- What Are Dividend Achievers? An Introduction
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
